Report from the visiting committee

Size: px
Start display at page:

Download "Report from the visiting committee"

Transcription

1 Section des Unités de recherche Report from the visiting committee Research unit : Cancer Virotherapy UMR_S 701 University Louis Pasteur - Strasbourg 1 February 2008

2 Section des Unités de recherche Report from the visiting committee Research unit : Cancer Virotherapy UMR_S 701 University Louis Pasteur Strasbourg 1 February 2008

3 Report from the visiting committee The research unit : Name of the research unit : Cancer Virotherapy Requested label : UMR_S INSERM N in case of renewal : U701 Head of the research unit : M. Jean ROMMELAERE University or school : University Louis Pasteur Strasbourg 1 Centre Allemand de Recherche sur le Cancer - DKFZ, University of Heidelberg Other institutions and research organization : INSERM Date(s) of the visit : February, 5 th of

4 Members of the visiting committee Chairman of the commitee : Ms. Anna SALVETTI, Lyon Other committee members : Ms. Hildegard BÜNING, Köln, Germany M. Jean DAVOUST, Paris Ms. Gilliane CHADEUF, Nantes CNU, CoNRS, CSS INSERM, représentant INRA, INRIA, IRD representatives : M. Jean-Michel HEARD, Paris, CSS INSERM representative Observers AERES scientific representative: M. François-Loïc COSSET University or school representative: None Research organization representative (s) : Ms. Christine TUFFEREAU, INSERM Ms. Ruth WELLENREUTHER, DKFZ Ms. Marie-Ange LUC, INSERM ADR de Strasbourg 3

5 Report from the visiting committee 1 Short presentation of the research unit Total number of persons : 43 Total number of scientists with permanent position : 8 (INSERM, CNRS and DKFZ) Number of postdoctoral fellows : 9 Number of PhD students : 8 Number of engineers, technicians and administrative assistants : 10 Number of HDR : 4, all of them have PhD students Number of PhD theses completed in the past four years : 9 ; mean duration of 39 months Number of publishing scientists according to AERES criteria : 5 out of 8 2 Preparation and execution of the visit The overall quality of the written document was good. The only criticism concerned the lack of introduction on parvovirus biology which made it difficult to fully appreciate the potential advantages of parvoviruses (PVs) compared with other oncolytic viruses. The visit started in the morning by a general presentation of the Unit by the head of th unit, followed by two specific presentations of teams 1 and 2. Each presentation was 20 min long and was followed by 25 min of questions in front of all the scientists who individually answered the questions. The morning sessions were followed by a discussion in front of posters prepared by scientists, post-docs and PhD students. The quality of oral and poster presentation was considered excellent by the committee members. The afternoon was dedicated to the meetings with technicians/engineers, scientists, and students/post-docs. One of the committee members met the technicians/engineers whereas the other members met the students/post-doc. All the members of the committee met the scientists. During this meeting, each scientist was asked to present him/herself to indicate his/her position in the Unit and his/her working conditions. A particular emphasis was given to the analysis of their publication record during the last four years and to their status concerning the obtainment of the HDR. 3 Overall appreciation of the activity of the research unit, of its links with local, national and international partners The Unit occupies a very specific research niche on oncolytic PVs. During the last four years the Unit has followed its initial objectives that were: 1) to provide proof-of-concept of the anti-tumoural activity of rodent PVs ; 2) to decipher the molecular mechanisms used by PV to kill cancer cells ; 3) to improve the oncolytic activity of PV ; 4) to assess the clinical relevance of this approach for cancer therapy. The Unit occupies a unique position as a French-German entity associated to INSERM and DKFZ, located in Heidelberg, and as a member of the Canceropole Grand-Est. It is also intimately connected to the Heidelberg biopole, the Heidelberg University Hospital and Strasbourg University and IRCAD Institute. From an international point of view, this Unit represents one of the leading laboratories in Europe and abroad involved in the study of autonomous parvoviruses and their applications as anti-tumoural agents. This specificity is also illustrated by its exceptional position regarding the number of approved patents. 4

6 4 Specific appreciation team by team and/or project by project Team 1 : Development of new virus-based strategies and identification of novel targets for cancer therapy Team 1 consists of 7 senior scientists (5 have permanent INSERM/DKFZ positions), 9 post-doc, 5 technicians and 5 students. It has published 29 articles, 8 reviews or book chapters, and 4 patents since its creation in The research activities of this team cover nearly all the objectives defined by the Unit. The activity of this team has first focused on the assessment of the anti-tumoural activity of PVs. Demonstration of the anti-tumoural properties of PV infection was obtained in two models. In a rat model of transplanted glioma, the team provided evidence that PV infection has the capacity to eradicate the tumour and to prevent relapse, without any obvious harmful effect on normal surrounding tissues. This preclinical validation of PVs as anti-tumour agents, as well as the demonstration that all human gliomas tested so far appeared susceptible to PV-induced lysis provide solid basis for the preparation of a clinical trial in patients with glioma at Heidelberg University Hospital. A clinical protocol is currently being elaborated, conditions for the preparation of clinical batches of PV have been set up, and a CRO is in charge of organising the trial. In a rat model of pancreatic cancer, PV infection was shown to reduce tumour growth and to improve recipient survival, especially when combined with chemotherapy. Further work is being done to confirm this preclinical demonstration with the aim to conduct a second clinical trial in this indication in the near future. The committee judged these works solid, convincing and promising, and encouraged the team to pursue efforts towards clinical assessment in the two proposed indications. The second objective of this team is to decipher the molecular mechanisms used by PVs to kill cancer cells. Several mechanisms potentially accounting for the anti-tumour effect of PVs have been identified. The direct cytotoxicity of PVs is related to specific biological activities of the viral protein NS1. This protein interacts with casein kinase II, triggering a cascade of events leading to reorganisation of the cytoskeleton (ERM proteins, gelsolin) favouring virus particle egress and release, altered expression of phospholipase A2, increased cathepsin activity in the cytoplasm and cell death through apoptosis or necrosis. Studies supporting these conclusions are straightforward, well conducted and demonstrative. Although PVs do not induce strong inflammatory responses, it is nevertheless presumable that the observed anti-tumoural action is at least in part mediated by immune responses. The team has performed several studies on the induction of innate immune responses to PV infected tumour cells, especially on the role of interferon ß. However, the activation of innate responses might be relayed by the initiation of adaptive responses mediated by appropriately activated, tumour antigen-loaded dendritic cells. Adaptive responses against PV infected tumour cells are likely responsible for the rejection of residual tumour cells, as illustrated by the observed anti-tumour vaccination effect. Accordingly, the group coducted a collaborative work showing that PV-induced cell death enhances immune response in vitro via increased cross-presentation by human dendritic cells. It would certainly be valuable to devote more efforts on this question. This would create a bridge with clinical trials, the scope of which could be broadened by immuno-monitoring the effects of oncolytic PV on the induction of anti-tumour B and T cell responses in enrolled patients. It is suggested that the implication of an immunologist would strengthen the developments in this research direction. Several other projects of team 1 are aimed at improving the oncolytic properties of PVs and at extending the use of PVs in other tumour models. They include combination with chemotherapy, targeting of histone deacetylase inhibitors in tumours induced by human papilloma viruses, the use of shrnas for the inhibition of key regulators, the retargeting of PVs toward cell surface components specifically expressed at the surface of cancer cells, the construction of hybrid viruses, using adenovirus vectors for the delivery of infectious PV genomes to tumours. These multiple projects appeared at an early stage of development. Since each requires substantial investments, it is suggested that the most promising ones are selected once results from preliminary studies are available, allowing better focus on most competitive approaches. Finally, an interesting project consists in the identification of new targets for anti-cancer treatment, using PVs as baits. The distribution of SGTA, a housekeeping nuclear protein, is deeply modified by PV infection. SGTA knock down induces cell mitotic arrest and kills tumour cells. Evidence was produced that SGTA contributes to correct positioning of chromosomes during metaphase. BAG6 is a partner of SGTA. These two proteins and their interaction are considered as potential targets for the development of anticancer treatments. 5

7 Team 2 : Therapeutic validation of parvoviral vectors Team 2 consists of 3 senior scientists (INSERM/DKFZ/CNRS), 1 guest scientist, 7 students and 3 engineers/technicians. This team has published 12 articles, 5 reviews or book chapters, and 2 patents since its creation in During the last four years the research activity of Team 2 was focused on the development of recombinant parvoviral vectors encoding, in addition to the NS1 protein, either immuno-stimulating or anti-angiogenic agents. Most notably, the team has achieved encouraging results in the demonstration of the anti-tumoural effect of MVM-based parvoviral vectors coding for TNF and IP10, in a mouse glioma model. However, the development of such vectors is hampered by a defect in infectivity as compared to the wild type virus. This will certainly require extensive biotechnological developments in order to be able to achieve higher infectious titres. Some specific analyses are already envisioned to solve this problem including, notably, the comparison of capsid structures of wild type and recombinant MVM particles. The second main project of this team was to assess the safety of PVs in the brain and to study the interaction between microglia and glioma cells. The first part of this study has provided essential results demonstrating that PVs are not toxic for normal brain cells. Studies are now underway to elucidate the mechanisms responsible for microglia-induced killing of glioma cells. Finally, a third project of team 2 consists in the search for viral and cellular determinants of cell permissiveness to parvovirus infection. This includes generation of chimeric MVM/H1 parvoviruses and analyses of cellular genes modulating PV infection. All together, these projects fit in the research activities of the Unit and are potentially important to provide new tools and insights for a more extensive use of PVs in cancer therapy. However, the adjustment between the projects and the human resources should be carefully examined. In particular, the team, which has lost two tenured scientists in the past four years, should consider hiring some experienced post-docs to strengthen all the projects related to parvoviral vectors development. In its current state, it is recommended that the team focus its efforts on some essential points to be able to significantly advance in this field. 5 Appreciation of resources and of the life of the research unit Human resources : Because of its bi-national nature the Unit has attracted many scientists and students from both nationalities. It also includes a large number of students and post-docs coming from many other countries. Within the last four years, a strong effort has been put in the recruitment of post-docs that actually constitute a very important part of the Unit (especially of team 1). As many other Units, there is a critical lack of technicians and administrative given the number of individual projects that are presently conducted and the development of a clinical trial. Materials and financial resources : The Unit is located in Heidelberg, within DKFZ (660 m 2 ) and Strasbourg, at IRCAD (188 m 2 ). It benefits from all infrastructures provided by both Institutes and surrounding campuses. From the financial point of view, the Unit has obtained during the last four years competitive grants and/or fellowships from German (von Humboldt Foundation, DKFZ), French (INCA, Cancéropôle Grand-Est) and international organizations (EMBO) that can fully support all its research activities. 6 Appreciation of the life in the research unit The meeting with the personnel of the Unit, including scientists, post-docs, students and technicians/engineers, showed that human relationships among all lab members are in general very good. Students are enthusiastic about the scientific interactions in the Unit and the Institute. There are several meetings and seminars organized within the Unit and DKFZ at which each member actively participate. The PhD students are asked at least once a year to present their result during department seminars. However, despite the existence of several scientific collaborations between individual team members, the committee felt that the large number of projects tended to split the two teams into several subgroups which is not favourable for creating a common strategic project. 6

8 7 Recommendations and advice Strong points : The committee members agreed that the Unit performs a very good research. They particularly appreciated the fundamental projects developed on parvovirus biology notably on aspects related to their tumour-specific cytotoxic effects and the development of novel synthetic targets for cancer therapy. The in vivo studies concerning the PVs anti-tumoural effects, in combination or not with chemotherapy, were also considered as very important in view of clinical applications. The committee also appreciated the number and quality of patent applications and considered that the Unit holds a unique worldwide position with regards to the development of PVs as anticancer agents. Recommendations : Given that the current Research Director will be retiring in six years, the committee estimates that it would be worth that tenured scientists in the Unit, together with the Research Director, start to develop a strategic plan for the future. Plans might include remodelling of the Unit with respect to teams and team leaders in order to focus on the most critical projects. The committee suggests that, in this context, the Unit considers the creation of a third team focusing on the analysis of the interactions between PV infected tumour cells and the immune system. Ideally, this could imply the recruitment of an experienced immunologist. 7

Report from the visiting commitee

Report from the visiting commitee Section des Unités de recherche Report from the visiting commitee Research unit: Biothérapies hépatiques University of Nantes January 2008 Section des Unités de recherche Report from the visiting committee

More information

Report from the visiting committee

Report from the visiting committee Section des Unités de recherche Report from the visiting committee Research unit : Cancer Immunotherapy University Paris 5 March 2008 Section des Unités de recherche Report from the visiting committee

More information

Section des Unités de recherche. Evaluation report. Research unit : Troubles du comportement alimentaire de l adolescent. University Paris 11

Section des Unités de recherche. Evaluation report. Research unit : Troubles du comportement alimentaire de l adolescent. University Paris 11 Section des Unités de recherche Evaluation report Research unit : Troubles du comportement alimentaire de l adolescent University Paris 11 Mars 2009 Section des Unités de recherche Rapport d'évaluation

More information

Section des Unités de recherche. Evaluation report. Research unit : Functional Genomics of Solid Tumors. Of University Paris 5

Section des Unités de recherche. Evaluation report. Research unit : Functional Genomics of Solid Tumors. Of University Paris 5 Section des Unités de recherche Evaluation report Research unit : Functional Genomics of Solid Tumors Of University Paris 5 March 2009 Section des Unités de recherche Evaluation report Research unit :

More information

Career Opportunities within the French Alliance for Life and Health Sciences

Career Opportunities within the French Alliance for Life and Health Sciences 1 Career Opportunities within the French Alliance for Life and Health Sciences Mireille Guyader, PhD Director, Inserm-USA Office INSERM KEY FIGURES (Year 2013) Budget: 970 M (~ $1.2 Billion) Human resources:

More information

HCERES report on research unit:

HCERES report on research unit: Research units HCERES report on research unit: Translational Gene Therapy for neuromuscular and retinal diseases Under the supervision of the following institutions and research bodies: Université de Nantes

More information

Section des Unités de recherche. Evaluation report. Research unit : Génétique moléculaire évolutive et médicale. of the University Paris 5

Section des Unités de recherche. Evaluation report. Research unit : Génétique moléculaire évolutive et médicale. of the University Paris 5 Section des Unités de recherche Evaluation report Research unit : Génétique moléculaire évolutive et médicale. of the University Paris 5 March 2009 Section des Unités de recherche Evaluation report Research

More information

Report from the visiting committee

Report from the visiting committee Section des Unités de recherche Report from the visiting committee Research unit : Therapy of striated muscles disorders University of Paris 6 April 2008 Section des Unités de recherche Report from the

More information

HCERES report on research unit: Under the supervision of the following institutions and research bodies: Biology of Cancer and Infection BCI

HCERES report on research unit: Under the supervision of the following institutions and research bodies: Biology of Cancer and Infection BCI Research units HCERES report on research unit: Biology of Cancer and Infection BCI Under the supervision of the following institutions and research bodies: Université Joseph Fourier - Grenoble - UJF Institut

More information

AERES report on the research unit

AERES report on the research unit Section des Unités de recherche AERES report on the research unit Génomique, bioinformatique et applications From the Conservatoire National des Arts et Métiers (CNAM) Mai 2010 Section des Unités de recherche

More information

Report from the visiting committee

Report from the visiting committee Section des Unités de recherche Report from the visiting committee Research unit : Pathologie et Virologie Moléculaire UMR 7151 University Denis Diderot Paris 7 January 2008 Section des Unités de recherche

More information

AERES report on the research unit

AERES report on the research unit Section des Unités de recherche AERES report on the research unit Neuroinflammation : imaging and therapy of multiple sclerosis From the Université Bordeaux 2 Victor Segalen INSERM (for the project) May

More information

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous

More information

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational

More information

Ariela Benigni. Biol.Sci.D., Ph.D. Curriculum Vitae

Ariela Benigni. Biol.Sci.D., Ph.D. Curriculum Vitae Ariela Benigni Biol.Sci.D., Ph.D. Curriculum Vitae Personal Data Name: Date and place of birth: Citizenship: E-mail: Ariela Benigni December 16, 1955 - Bergamo, Italy Italian ariela.benigni@marionegri.it

More information

AERES report on the research unit

AERES report on the research unit Section des Unités de recherche AERES report on the research unit Center for Human Immunology From the Pasteur Institute May 2010 Section des Unités de recherche AERES report on the research unit Center

More information

AERES report on the research unit

AERES report on the research unit Section des Unités de recherche AERES report on the research unit Fonction structure et inactivation d ARN bactériens From the University Rennes 1 INSERM December 2010 Section des Unités de recherche AERES

More information

Ecole Normale Supérieure (ENS)

Ecole Normale Supérieure (ENS) Section des Unités de recherche Evaluation report Research unit: Laboratoire de Physique Théorique (LPT ENS) UMR 8549 Ecole Normale Supérieure (ENS) March 2009 Section des Unités de recherche Evaluation

More information

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction

More information

AERES report on the research unit

AERES report on the research unit Section des Unités de recherche AERES report on the research unit Nutrition, Growth and Cancer From the University François-Rabelais INSERM January 2011 Section des Unités de recherche AERES report on

More information

AERES report on the Federative Research Structure:

AERES report on the Federative Research Structure: Section des Unités de recherche AERES report on the Federative Research Structure: Cell and Tissue Engineering From the: Université de Franche-Comté March 2011 Section des Unités de recherche AERES report

More information

Section des Unités de recherche. Evaluation report. Research unit : Génétique humaine des maladies infectieuses. University Paris 5

Section des Unités de recherche. Evaluation report. Research unit : Génétique humaine des maladies infectieuses. University Paris 5 Section des Unités de recherche Evaluation report Research unit : Génétique humaine des maladies infectieuses University Paris 5 March 2009 Section des Unités de recherche Evaluation report Research unit

More information

A Letter from MabVax Therapeutics President and Chief Executive Officer

A Letter from MabVax Therapeutics President and Chief Executive Officer A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the

More information

JUNE 2-3, 2014 CONNECT.

JUNE 2-3, 2014 CONNECT. JUNE 2-3, 2014 CONNECT. GROW. SUCCEED. THIRD INDUSTRIAL CELL CULTURE TECHNOLOGY CONFERENCE JUNE 2-3, 2014 Laupheim s historical castle, Schloss Großlaupheim, Germany Rentschler Biotechnologie GmbH is delighted

More information

HCERES report on research unit: Under the supervision of the following institutions and research bodies:

HCERES report on research unit: Under the supervision of the following institutions and research bodies: Research units HCERES report on research unit: Cellules Stromales, Homeostasie, Plasticité et Regénération Tissulaire STROMALab Under the supervision of the following institutions and research bodies:

More information

University Versailles-Saint-Quentin en Yvelines

University Versailles-Saint-Quentin en Yvelines Section des Unités de recherche Evaluation report Research unit Pathophysiology and Clinical Pharmacology of Pain University Versailles-Saint-Quentin en Yvelines March 2009 Section des Unités de recherche

More information

AERES report on the research unit

AERES report on the research unit Section des Unités de recherche AERES report on the research unit Hypoxia, Patho-Physiology From the University Grenoble 1 INSERM May 2010 Section des Unités de recherche AERES report on the research unit

More information

Section des Unités de recherche. Evaluation Report. Research unit : Food allergy laboratory INRA

Section des Unités de recherche. Evaluation Report. Research unit : Food allergy laboratory INRA Section des Unités de recherche Evaluation Report Research unit : Food allergy laboratory INRA March 2009 2 Section des Unités de recherche Evaluation report Research unit : Food allergy laboratory INRA

More information

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.

More information

ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES

ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES DESCRIPTION OF GRANT MECHANISM The Alliance for Lupus Research (ALR) is an independent,

More information

2016 POST-DOCTORAL PROGRAM Applicant Guide

2016 POST-DOCTORAL PROGRAM Applicant Guide 2016 POST-DOCTORAL PROGRAM Applicant Guide POST-DOCTORAL FELLOWSHIP PROGRAM 2016 Applicant guide The Initiative of Excellence of the University of Bordeaux (IdEx Bordeaux) is opening positions for postdoctoral

More information

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination

More information

cause harmful and unwanted toxicity to normal cells. The therapeutic index of chemotherapy is

cause harmful and unwanted toxicity to normal cells. The therapeutic index of chemotherapy is Using Viruses to Kill Cancer: Investigating the role of in vitro cell differentiation in HSV-1 double-mutant KM110red infection of hfob and U2OS cells Natalie Raso Background In the successful development

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 23 July 1998 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL

More information

The Need for a PARP in vivo Pharmacodynamic Assay

The Need for a PARP in vivo Pharmacodynamic Assay The Need for a PARP in vivo Pharmacodynamic Assay Jay George, Ph.D., Chief Scientific Officer, Trevigen, Inc., Gaithersburg, MD For further infomation, please contact: William Booth, Ph.D. Tel: +44 (0)1235

More information

Editorial. Yves Levy, Executive Director

Editorial. Yves Levy, Executive Director Editorial Yves Levy, Executive Director I am delighted to announce the creation of a new research centre: the Vaccine Research Institute (VRI). The VRI addresses the unprecedented challenge of developing

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES

More information

ATIP Avenir Program 2014. Applicant s guide

ATIP Avenir Program 2014. Applicant s guide ATIP Avenir Program 2014 Applicant s guide Important dates: - November 29 th 2013: deadline for the online submission, the mailing of the hard copy of the scientific project, and the letters of recommendation

More information

Report from the visiting committee

Report from the visiting committee Section des Unités de recherche Report from the visiting committee Research unit: Laboratoire de Chimie et Biochimie des Complexes Moléculaires (LCBCM) - UMR 7576 Ecole Nationale Supérieure de Chimie de

More information

Basic Overview of Preclinical Toxicology Animal Models

Basic Overview of Preclinical Toxicology Animal Models Basic Overview of Preclinical Toxicology Animal Models Charles D. Hebert, Ph.D., D.A.B.T. December 5, 2013 Outline Background In Vitro Toxicology In Vivo Toxicology Animal Models What is Toxicology? Background

More information

Research Unit Biochimie Bacté AgroParis Tech

Research Unit Biochimie Bacté AgroParis Tech Section des Unités de recherche Evaluation report Research unit Biochimie Bactérienne AgroParisTech March 2009 Section des Unités de recherche Evaluation report Research unit Biochimie Bactérienne AgroParisTech

More information

International Symposium on Malignant Mesothelioma 2011 -- curemeso.org

International Symposium on Malignant Mesothelioma 2011 -- curemeso.org Measles virotherapy for malignant mesothelioma Manish R. Patel, D.O. Assistant Professor of Medicine University of Minnesota June 25, 2011 Medical Treatment of Mesothelioma Majority of patients are not

More information

Cytotoxic and Biotherapies Credentialing Programme Module 2

Cytotoxic and Biotherapies Credentialing Programme Module 2 Cytotoxic and Biotherapies Credentialing Programme Module 2 1. The Cell Cycle 2. Cancer Therapies 3. Adjunctive Therapies On completion of this module the RN will State the difference between a normal

More information

Chapter 8. Summary and Perspectives

Chapter 8. Summary and Perspectives Chapter 8 Summary and Perspectives 131 Chapter 8 Summary Overexpression of the multidrug resistance protein MRP1 confer multidrug resistance (MDR) to cancer cells. The contents of this thesis describe

More information

A Genetic Analysis of Rheumatoid Arthritis

A Genetic Analysis of Rheumatoid Arthritis A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.

More information

Decrease the impact of neurofibromatosis and Schwannomatosis.

Decrease the impact of neurofibromatosis and Schwannomatosis. Congressiionalllly Diirectted Mediicall Research Programs Neuroffiibromattosiis Research Program (NFRP)) Vision Decrease the impact of neurofibromatosis and Schwannomatosis. Mission Promote research directed

More information

Journée des Industriels du Réseau TRIGGERSEP

Journée des Industriels du Réseau TRIGGERSEP Journée des Industriels du Réseau TRIGGERSEP Djillali ANNANE Hôpital Raymond Poincaré (AP-HP) Lab Cell Death Inflamation & Infection UMR1173 UVSQ/INSERM Mercredi 3 juin 2015 Institut Pasteur Paris Expertise:

More information

Bioethics Education in Professional Science Master s Programs at California State University Channel Islands

Bioethics Education in Professional Science Master s Programs at California State University Channel Islands ETHICS AND THE PSM Bioethics Education in Professional Science Master s Programs at California State University Channel Islands Ching-Hua Wang, M.D., Ph.D., Director of MS Biotechnology and Bioinformatics

More information

Study Program Handbook Biochemistry and Cell Biology

Study Program Handbook Biochemistry and Cell Biology Study Program Handbook Biochemistry and Cell Biology Bachelor of Science Jacobs University Undergraduate Handbook BCCB - Matriculation Fall 2015 Page: ii Contents 1 The Biochemistry and Cell Biology (BCCB)

More information

Stem cells and motor neurone disease

Stem cells and motor neurone disease Stem cells and motor neurone disease F Stem cell research has fuelled hope of a treatment for a variety of conditions. This information sheet explains what these cells are and includes details of the current

More information

Ph.D. in Molecular Medicine

Ph.D. in Molecular Medicine Ph.D. in Molecular Medicine and Translational Research College of Medicine 1. Introduction: The College of Medicine, while consolidating on its undergraduate innovative educational programs, decided to

More information

HCERES report on research unit: Under the supervision of the following institutions and research bodies:

HCERES report on research unit: Under the supervision of the following institutions and research bodies: Research units HCERES report on research unit: Pathophysioloy, Diagnosis and Treatments of Bone Diseases LYOS Under the supervision of the following institutions and research bodies: Université Claude

More information

HCERES report on research unit:

HCERES report on research unit: Research units HCERES report on research unit: Actions for oncogenesis understanding and Target Identification in ONcology ACTION Under the supervision of the following institutions and research bodies:

More information

Achievements Report CURING CANCER. Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for

Achievements Report CURING CANCER. Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for Achievements Report August 2015 CURING CANCER Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for cancer? Since cancer is complex and comes in many forms, its

More information

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Evaluation of Medicines for Human Use London, 10 October 2007 Doc. Ref. COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON POTENCY TESTING OF CELL BASED IMMUNOTHERAPY

More information

INSERM/ A. Bernheim. Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance

INSERM/ A. Bernheim. Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance A. Bernheim Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance OVER-MyR is funded by the European Commission within its FP7 specific

More information

Research units. Laboratory of Microbial Molecular Genetics LMGM

Research units. Laboratory of Microbial Molecular Genetics LMGM Research units HCERES report on research unit: Laboratory of Microbial Molecular Genetics LMGM Under the supervision of the following institutions and research bodies: Université Toulouse 3 - Paul Sabatier

More information

ATIP Avenir Program 2016 Young group leader. Applicant s guide

ATIP Avenir Program 2016 Young group leader. Applicant s guide ATIP Avenir Program 2016 Young group leader Applicant s guide Important dates - November 26 th 2015: deadline for the online submission, the mailing of the hard copy of the scientific project, and the

More information

International training programme

International training programme International training programme Science has no native land, as knowledge is the heritage of humankind, the torch that lights up the world. Louis Pasteur The Institut Pasteur International Network (RIIP)

More information

HCERES report on research unit: Under the supervision of the following institutions and research bodies:

HCERES report on research unit: Under the supervision of the following institutions and research bodies: Research units HCERES report on research unit: Cancer Research Center of Toulouse CRCT Under the supervision of the following institutions and research bodies: Université Toulouse 3 Paul Sabatier Centre

More information

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5 European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS

More information

Issues. Does the academe have as a goal or an obligation, the development of its discoveries for human benefit?

Issues. Does the academe have as a goal or an obligation, the development of its discoveries for human benefit? ELLEN PURÉ, Ph.D. Issues Does the academe have as a goal or an obligation, the development of its discoveries for human benefit? Can the academic review process support individual career development in

More information

Overview of Phase 1 Oncology Trials of Biologic Therapeutics

Overview of Phase 1 Oncology Trials of Biologic Therapeutics Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of

More information

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.

More information

Future Oncology: Technology, Products, Market and Service Opportunities

Future Oncology: Technology, Products, Market and Service Opportunities Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter

More information

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology The Master Degree in Medical Laboratory Sciences / Clinical Microbiology, Immunology or

More information

What do Birmingham postgraduates do?

What do Birmingham postgraduates do? 1 Essential information What do Birmingham postgraduates do? School of First destinations of postgraduates Analysis of first employment destinations of postgraduates from the College of Medical and Dental

More information

Immunotherapy of Uveal Melanoma

Immunotherapy of Uveal Melanoma Eye Am Not Alone (EANA) Patient Retreat Saturday Session - March 3, 2012 Immunotherapy of Uveal Melanoma Do not distribute or copy without the express permission of the Ocular Melanoma Foundation (OMF).

More information

Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center

Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center Bodnar s Law Simple Things are Important Very Simple Things are Very Important

More information

NATIONAL HEALTH COUNCIL

NATIONAL HEALTH COUNCIL NATIONAL HEALTH COUNCIL RESOLUTION Nº 340, 8 TH JULY 2004 The National Health Council Plenary Assembly, in its 144 th Ordinary Meeting, held from the 7 th to the 8 th July 2004, in the use of its regimental

More information

Non-clinical development of biologics

Non-clinical development of biologics Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service

More information

Corporate Presentation June 2, 2015

Corporate Presentation June 2, 2015 Corporate Presentation June 2, 2015 SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these

More information

Ph.D. Program Molecular Microbiology and Immunology (MMI) Saint Louis University School of Medicine

Ph.D. Program Molecular Microbiology and Immunology (MMI) Saint Louis University School of Medicine Ph.D. Program Molecular Microbiology and Immunology (MMI) Saint Louis University School of Medicine I. Overview The Department of Molecular Microbiology and Immunology and Immunology (MMI) offers a graduate

More information

The Four Pillars of Cancer Therapy

The Four Pillars of Cancer Therapy Improving the Overall Understanding of Immunotherapy in Multiple Myeloma Webinar 2, August 19, 2015 Myeloma Vaccines: A New Use of a Time-Tested Treatment The Four Pillars of Cancer Therapy Surgery Radiation

More information

Mechanism of short-term ERK activation by electromagnetic fields at mobile phone frequencies. Biochemistry Journal. August 1, 2007 405, pp.

Mechanism of short-term ERK activation by electromagnetic fields at mobile phone frequencies. Biochemistry Journal. August 1, 2007 405, pp. Mechanism of short-term ERK activation by electromagnetic fields at mobile phone frequencies 1 Biochemistry Journal August 1, 2007 405, pp. 559 568 Joseph Friedman, Sarah Kraus, Yirmi Hauptman, Yoni Schiff

More information

HUNTINGTON S DISEASE THERAPIES RESEARCH UPDATE

HUNTINGTON S DISEASE THERAPIES RESEARCH UPDATE HUNTINGTON S DISEASE MULTIDISCIPLINARY CLINIC HUNTINGTON S DISEASE THERAPIES RESEARCH UPDATE From gene to treatments The gene that causes Huntington s disease (HD) was discovered in 1993. Since then, enormous

More information

TECHNICAL INSIGHTS TECHNOLOGY ALERT

TECHNICAL INSIGHTS TECHNOLOGY ALERT TECHNICAL INSIGHTS TECHNOLOGY ALERT UNLOCKING BREAST CANCER TUMORS' DRUG RESISTANCE A troubling phenomenon in breast cancer treatment is that some patients tumors become resistant to treatments over time.

More information

7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology)

7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology) 7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology) Students should fulfill a total of 44 credit hours: 1- Compulsory courses: 14 credit hours. 1504801, 1504802, 1504803,

More information

EMBL. International PhD Training. Mikko Taipale, PhD Whitehead Institute/MIT Cambridge, MA USA

EMBL. International PhD Training. Mikko Taipale, PhD Whitehead Institute/MIT Cambridge, MA USA EMBL International PhD Training Mikko Taipale, PhD Whitehead Institute/MIT Cambridge, MA USA Why create an EMBL? The structure of DNA had been solved and first protein structures were being identified

More information

HUMAN GENETIC TESTING PATENTS : ELIGIBILITY AND ENFORCEMENT

HUMAN GENETIC TESTING PATENTS : ELIGIBILITY AND ENFORCEMENT HUMAN GENETIC TESTING PATENTS : ELIGIBILITY AND ENFORCEMENT FRENCH APPROACH DENISE HIRSCH HEAD OF IP THE ENVIRONNENT Patentability of living organism was a public debate in France focusing on ethical issues

More information

Under the supervision of the following institutions and research bodies:

Under the supervision of the following institutions and research bodies: Research units HCERES report on unit: Fruit Biology and Pathology BFP Under the supervision of the following institutions and research bodies: Institut National de la Recherche Agronomique - INRA Université

More information

Immunology Ambassador Guide (updated 2014)

Immunology Ambassador Guide (updated 2014) Immunology Ambassador Guide (updated 2014) Immunity and Disease We will talk today about the immune system and how it protects us from disease. Also, we ll learn some unique ways that our immune system

More information

Creating the Future Pierre and Marie Curie University. www.upmc.fr

Creating the Future Pierre and Marie Curie University. www.upmc.fr Creating the Future Pierre and Marie Curie University www.upmc.fr UPMC: the Leading French Scientific and Medical University Every day, UPMC demonstrates how education and research create important synergies.

More information

How To Treat Leukaemia With Cord Blood Stem Cell

How To Treat Leukaemia With Cord Blood Stem Cell Cord blood for the treatment of acute lymphoblastic leukemia in young children By Caitlin McGreevy Kiara Paramjothy Pass with Merit RESEARCH PAPER BASED ON PATHOLOGY LECTURES AT MEDLINK 2011 1 Abstract:

More information

BioMmune Technologies Inc. Corporate Presentation 2015

BioMmune Technologies Inc. Corporate Presentation 2015 BioMmune Technologies Inc Corporate Presentation 2015 * Harnessing the body s own immune system to fight cancer & other autoimmune diseases BioMmune Technologies Inc. (IMU) ABOUT A public biopharmaceutical

More information

UPBM CURRICULAR BROCHURE

UPBM CURRICULAR BROCHURE UPBM CURRICULAR BROCHURE Undergraduate Program in Biology and Medicine Contents Academic Year 2015-16 About the Undergraduate Program in Biology and Medicine...pg. 1 Undergraduate Majors...pg. 2-3 Getting

More information

Chapter 16 Reproductive Technology, Gene Therapy, and Stem Cells (modified)

Chapter 16 Reproductive Technology, Gene Therapy, and Stem Cells (modified) Chapter 16 Reproductive Technology, Gene Therapy, and Stem Cells (modified) Assisted Reproductive Technologies (ART) Artificial insemination (AI) In vitro fertilization (IVF) Gamete intrafallopian transfer

More information

BIOSKETCH. Degrees: Cand. real. 1971, Dr. philos. 1978. University of Bergen, Norway

BIOSKETCH. Degrees: Cand. real. 1971, Dr. philos. 1978. University of Bergen, Norway BIOSKETCH Johan R. Lillehaug Born: 25.09.45 Home address: Ibsensgate 89, 5052 Bergen Nationality: Norwegian Present position: Department Chairman (2004- ) and Professor in biotechnology (1987-), Department

More information

Evaluation of the role of gene polymorphisms in anticancer drug efficacy using in vitro models

Evaluation of the role of gene polymorphisms in anticancer drug efficacy using in vitro models Group members and Contact details Jacques Robert graduated in medicine from the University of Strasbourg in 1974 and received hi Research projects: The objectives of our group are: (1) to identify preclinical

More information

Veterinary Education in France: The National Veterinary School in Toulouse

Veterinary Education in France: The National Veterinary School in Toulouse Veterinary Education in France: The National Veterinary School in Toulouse Pr. Alain MILON DVM, PhD Dean of ENVT QuickTime et un décompresseur sont requis pour visionner cette image. Alfort French National

More information

2012-Annual Report. Annual Report 2012 - Institut Pasteur

2012-Annual Report. Annual Report 2012 - Institut Pasteur 2012-Annual Report Name of the Department: Name of the Structure: Direction Médicale Pôle Intégré de Recherche Clinique (PIRC) Secondary Affiliation: - Head of the laboratory: Dr Cécile Delval, Cecile.delval@pasteur.fr

More information

M110.726 The Nucleus M110.727 The Cytoskeleton M340.703 Cell Structure and Dynamics

M110.726 The Nucleus M110.727 The Cytoskeleton M340.703 Cell Structure and Dynamics of Biochemistry and Molecular Biology 1. Master the knowledge base of current biochemistry, molecular biology, and cellular physiology Describe current knowledge in metabolic transformations conducted

More information

What s New in Ovarian Cancer Research? Novel Therapeutics for Ovarian Cancer

What s New in Ovarian Cancer Research? Novel Therapeutics for Ovarian Cancer What s New in Ovarian Cancer Research? Novel Therapeutics for Ovarian Cancer Scott Kaufmann, M.D., Ph.D. Mayo Clinic Division of Oncology Research October 27, 2012 Where we are now. Surgery Front-line

More information

TRANSGENE SA, FRANCE 2. INSTITUT PASTEUR, FRANCE On behalf. AFEF 2013, Lille 02 nd October 2013

TRANSGENE SA, FRANCE 2. INSTITUT PASTEUR, FRANCE On behalf. AFEF 2013, Lille 02 nd October 2013 A MULTIVALENT ADENOVIRUS-BASED IMMUNOTHERAPEUTIC FOR TREATMENT OF CHRONIC HEPATITIS B INDUCES BROAD, ROBUST AND POLYFUNCTIONAL T CELLS IN NAIVE MICE AND EXERT AN EARLY ANTIVIRAL EFFECT IN HBV TOLERANT

More information

Vaccines Researches for the Future:

Vaccines Researches for the Future: ITMO Microbiologie et maladies infectieuses Vaccines Researches for the Future: The corevac initiative Pr Brigitte AUTRAN Institute Infection-Cancer-Immunity, UPMC, Paris Pr Jean François Delfraissy Institute

More information

FACULTY OF MEDICAL SCIENCE

FACULTY OF MEDICAL SCIENCE Doctor of Philosophy Program in Microbiology FACULTY OF MEDICAL SCIENCE Naresuan University 171 Doctor of Philosophy Program in Microbiology The time is critical now for graduate education and research

More information

Future strategies for myeloma: An overview of novel treatments In development

Future strategies for myeloma: An overview of novel treatments In development Future strategies for myeloma: An overview of novel treatments In development Dr. Matthew Streetly Guys and St. Thomas NHS Trust How far have we come? Melphalan and prednisolone VAD Autologous SCT Thalidomide

More information

AERES report on the research unit

AERES report on the research unit Section des Unités de recherche AERES report on the research unit Genetics, Reproduction and Development From the Université d Auvergne Université Blaise Pascal INSERM CNRS March 2011 Section des Unités

More information

Opposition against European Patent EP 1 456 346 B1

Opposition against European Patent EP 1 456 346 B1 Opposition against European Patent EP 1 456 346 B1 Title: NOVEL ECDYSONE RECEPTOR/INVERTEBRATE RETINOID X RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM Application number: 02714955.8 Proprietor: Intrexon

More information